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Abstract
Background:  Polyamines regulate important cellular functions and polyamine dysregulation
frequently occurs in cancer. The objective of this study was to use a systems approach to study the
relative effects of PG-11047, a polyamine analogue, across breast cancer cells derived from
different patients and to identify genetic markers associated with differential cytotoxicity.
Methods: A panel of 48 breast cell lines that mirror many transcriptional and genomic features
present in primary human breast tumours were used to study the antiproliferative activity of PG-
11047. Sensitive cell lines were further examined for cell cycle distribution and apoptotic response.
Cell line responses, quantified by the GI50 (dose required for 50% relative growth inhibition) were
correlated with the omic profiles of the cell lines to identify markers that predict response and
cellular functions associated with drug sensitivity.
Results: The concentrations of PG-11047 needed to inhibit growth of members of the panel of
breast cell lines varied over a wide range, with basal-like cell lines being inhibited at lower
concentrations than the luminal cell lines. Sensitive cell lines showed a significant decrease in S
phase fraction at doses that produced little apoptosis. Correlation of the GI50 values with the omic
profiles of the cell lines identified genomic, transcriptional and proteomic variables associated with
response.
Conclusions: A 13-gene transcriptional marker set was developed as a predictor of response to
PG-11047 that warrants clinical evaluation. Analyses of the pathways, networks and genes
associated with response to PG-11047 suggest that response may be influenced by interferon
signalling and differential inhibition of aspects of motility and epithelial to mesenchymal transition.
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Background
Low molecular weight polycationic polyamines are found
in cells in millimolar concentrations and are essential for
mammalian cell proliferation, survival and function [1].
Polyamines are associated with nucleic acid metabolism,
maintenance of chromatin structure, regulation of specific
gene expression, ion channel modulation and membrane
stability [1]. The synthesis and catabolism of the
polyamines is exquisitely regulated. Polyamines and their
biosynthetic enzymes are co-ordinately regulated with
growth controls, and polyamine dysregulation frequently
occurs in cancer [2]. Thus, targeting this pathway may pro-
vide therapeutic advantage in cancer and other hyperpro-
liferative diseases. The polyamine pathway is a
downstream target of known oncogenes and the inhibi-
tion of polyamine synthesis disrupts the action of these
genes [2]. It also appears that the polyamines are critical
to the activity of a number of histone deacetylase inhibi-
tors [3]. Thus, the polyamine pathway is a site of thera-
peutic intervention that is common to, and distal to, a
number of validated targets and drugs that interfere with
polyamine metabolism and function should have utility
both alone and in combination with other agents.
Several approaches to modulating the polyamine path-
way have been utilized to date [2]. Targeting the key bio-
synthetic enzymes has yielded important scientific tools
and some clinical success. Difluoromethylornithine, an
inhibitor of the first enzyme in the mammalian
polyamine biosynthetic pathway, ornithine decarboxy-
lase, is approved for use in trypanosomiasis and has
shown promise in the therapy of brain tumours [4]. It has
also displayed excellent activity as a chemoprevention for
colon polyps, when used in combination with sulindac
[5]. However, enzyme inhibitors of the polyamine path-
way have generally had limited clinical success to date. A
second approach uses dysfunctional synthetic polyamine
analogues to competitively inhibit natural polyamine
functions. Many of the analogues synthesized to date take
advantage of the self-regulatory properties of the natural
polyamines and significantly modulate the activity of the
biosynthetic and catabolic enzymes, lowering endog-
enous polyamine levels. Additionally, some of these com-
pounds may function as polyamine mimetics, binding to
normal polyamine binding sites in the cell to attenuate
normal functions [6].
The compound utilized in this study, PG-11047, is a sec-
ond generation polyamine analogue of N1, N12-bisethyl-
spermine (BESpm) [7]. PG-11047 is a conformationally
restricted analogue of BESpm with a cis double bond
between the central carbons. It is thought to inhibit pro-
liferation and other cellular functions by competing with
natural polyamines. It is active against human cancer cells
both in vitro [7] and in mouse xenografts [8]. It has shown
positive results in the treatment of lymphoma in a phase
I human clinical trial as well as in a phase II study for pros-
tate cancer. It has thus far displayed a very benign toxicity
profile and a phase I monotherapy trial is nearing comple-
tion [2]. It is also in a phase 1b trial in combination with
each of seven different approved drugs (Clinical Trial
Identifier: NCT00705874). For the combination of PG-
11047 with docetaxel or gemcitabine maximally tolerated
doses have been reached. Dose escalation of PG-11047 in
combination with either bevacizumab, erlotinib, cispla-
tin, 5-fluorouracil or sunitinib malate is ongoing. With
phase II trials emerging as the next step in the evaluation
of the efficacy of PG-11047, specific pre-clinical studies
are being undertaken to help guide the choice of appropri-
ate clinical subjects. Such preclinical studies include
extensive in vitro screens in order to provide an insight
into the subpopulations of specific cancer types that
might be amenable to treatment with PG-11047, while at
the same time identifying putative molecular markers for
the prediction of sensitivity or resistance to treatment.
Breast cancers develop through multiple genetic and epi-
genetic changes resulting in a wide range of cancer pheno-
types. The resulting breast cancers have been classified,
based on their gene expression profiles, into five distinct
subtypes that are associated with diverse tumour charac-
teristics and clinical outcome [9,10] and into three groups
based on their genomic characteristics [11]. Treatment of
a limited number of human breast cancer cell lines in cul-
ture with PG-11047 has been reported to inhibit cell
growth and/or induce cell death [12,13]. To better deline-
ate the response of breast cancer cells to PG-11047, we
studied the antiproliferative activity of this drug in a panel
of 48 breast cell lines (including six non-malignant breast
cell lines) that mirror many transcriptional and genomic
features present in primary human breast tumours [14].
The initial characterization of this panel shows that the
cell lines are comprised of three subtypes designated basal
A, basal B and luminal. The basal A subtype corresponds
most closely to tumours designated as basal-like [15,16]
by expression profiling while the basal B subtype corre-
sponds most closely to tumours designated as claudin-
low [17] (and Spellman et al., personal communication).
The basal A and basal B subtypes will be referred to as
basal and claudin-low, respectively, in the following text.
Our studies show that basal subtype breast cancer cell
lines are most sensitive to treatment with PG-11047 based
on the dose required to inhibit 50% relative growth
(GI50). Correlations between cell line responses quanti-
fied by the GI50 and the transcriptional and genomic char-
acteristics of these cell lines identified a set of 250 genes
that are associated with response. A signature comprised
of 13 of these genes is proposed as a predictor of response
to PG-11047 treatment in breast tumours.BMC Medicine 2009, 7:77 http://www.biomedcentral.com/1741-7015/7/77
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Methods
Breast cancer cell lines
Breast cancer cell lines were obtained from the American
Type Culture Collection and from collections developed
in the laboratories of Drs Steve Ethier (Karmanos Cancer
Center, MI, USA) and Adi Gazdar (UT Southwestern Med-
ical Center, TX, USA). Forty of the cell lines were charac-
terized in great detail by Neve et al. [14], eight were
acquired recently and characterized in similar fashion for
subtype classification (Spellman et al., personal commu-
nication). The recurrent genome copy number abnormal-
ities in the collection of cell lines was similar to those in
primary tumours, while hierarchical analysis of the tran-
scriptional features of the cell lines defined three clusters
designated luminal, basal and claudin-low [14].
Cell growth inhibition assay and data analysis
Cells were plated at proper density (from 1000 to 15,000
cells/100 μl/well, depending on the cell line) in 96-well
plates, so that they remained in logarithmic growth at the
time of assay. The cells were allowed to attach overnight
before being exposed to the polyamine analogue PG-
11047 for 72 h. PG-11047 (N1,  N12bis(ethyl)-6,7-
dehydrospermine tetrahydrochloride, previously known
as SL-11047 and CGC-11047) was obtained from Progen
Pharmaceuticals (CA, USA) and a stock solution of 100
mM was prepared in sterile water. For the dose response
study, a set of nine doses (final concentration from 5 mM
to 13 nM) in 1:5 serial dilution were added in triplicate
wells. Adenosine triphosphate content was measured as
an estimate of relative cell number using the CellTiter-Glo
(CTG) Luminescent Cell Viability Assay (Promega, WI,
USA), with slight modification form manufacturer's pro-
tocol, at day 0 (time when drug was added) and day 3 of
drug exposure. Briefly, the CTG reagent was diluted with
phosphate-buffered saline (PBS; 1:1, volume: volume)
and the culture media was removed from the 96-well plate
prior to adding 50 μl per well of the diluted CTG reagent.
Luminescence from the assay was recorded using BIO-TEK
FLx800.
Metrics describing the drug effects were calculated accord-
ing to the methods described by the NCI/NIH DTP
Human Tumor Cell Line Screen [18] and by Monks et al.
[19]. The % growth curve is calculated as ((T-T0)/(C- T0))
×100, where T0 is the CTG luminescence at day 0, C is the
untreated control CTG luminescence at day 3 and T is the
CTG luminescence at the test concentration. The dose
response curve was fitted with GraphPad Prism4 software
(GraphPad Software, Inc, CA, USA). The GI50 and TGI
(total growth inhibition) values were determined as the
drug concentrations that caused 50% and 0% relative
growth at 72 h drug exposure, respectively.
Bromodeoxyuridine (BrdUrd) labelling and cell cycle 
analyses
The fractions of cells in the G1-S and G2 M phases of the
cell cycle were estimated from measurements of BrdUrd-
DNA distributions [20]. For this, cells were set up the
same as in the cell growth inhibition assay and treated
with PG-11047 at three different doses of 0.3, 10 or 300
μM for 48 h and 72 h. A positive control of 10 nM
docetaxel treatment was included in all experiments. Cells
were pulse labelled with a final BrdUrd concentration of
10 μM for 30 min, then fixed with 70% ethanol overnight
in the 96-well plate. Fixed cells were denatured with 2N
hydrochloric acid for 30 min and then incubated with pri-
mary anti-BrdUrd antibody (BD Biosciences, CA, USA;
1:100 dilutions), followed by staining with a secondary
antibody (1:500 dilution) labelled with Alexa-488 and
counterstained with Hoechst 33342 (1:2000 dilution).
The cells were then placed in PBS and Hoechst 33342 and
Alexa-488 images were acquired for cells in each well
using an ArrayScan imaging system (Cellomics Inc, PA,
USA). The Hoechst images were segmented to localize
nuclei and Hoechst fluorescence was measured for each
nucleus as an estimate of relative DNA content. Alexa-488
fluorescence was measured for each segmented nucleus as
an estimate of incorporated BrdUrd. Several thousand
cells were measured for each well and the Hoechst 33342
and Alexa-488 results were combined to produce a bivar-
iate BrdUrd-DNA distribution similar to that produced
using flow cytometry [20]. The bivariate distributions for
each well were analysed to determine the fractions of cells
in the G1, S and G2 M phases of the cell cycle using FlowJo
software (Tree Star, Inc, OR, USA). Flow cytometric
BrdUrd-DNA distributions measured for several replicate
experiments produced cell cycle fractions similar to those
obtained using the imaging approach (data not shown).
Apoptosis assay
The extent of PG-11047-induced apoptosis was deter-
mined using the Caspase-Glo 3/7 assay kit from Promega
(WI, USA). A positive control of 10 nM docetaxel treat-
ment was included in all experiments. After incubation of
cells with PG-11047 at the specified concentrations for 48
h or 72 h, 50 μl Caspase-Glo reagent was added to wells.
After an incubation time of 1 h, luminescence was meas-
ured using a BIO-TEK FLx800 luminometer. Parallel
experiments were set up to determine the relative number
of viable cells using the CTG assay, as described above, in
order to normalize the caspase activity by relative cell den-
sity.
Statistical analysis of molecular markers associated with 
response
The PG-11047 GI50 levels for all cell lines were correlated
with the molecular features measured for each cell linesBMC Medicine 2009, 7:77 http://www.biomedcentral.com/1741-7015/7/77
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(microarray profiles for RNA expression and genome copy
number and Western blot based protein profiles) as
reported by Neve et al. [14]. We used a statistical approach
based on adaptive linear splines in order to identify the
molecular correlates of response to PG-11047. These are
variants of the linear splines method described previously
[21]. Briefly, we used a non-parametric regression method
to model non-linear relationships between molecular cor-
relates and response. The goodness of fit was assessed by
evaluating a P-value corresponding to the F-statistic for
the fit [21]. P-values were corrected for multiple hypothe-
ses testing using the false discovery rate method [22]. This
process identified 250 genes whose transcripts were asso-
ciated with response. From these, a 13 gene set was devel-
oped in order to predict a quantitative response among
the cell lines using Monte Carlo cross-validation (MCCV)
[23]. The complete panel of cell lines was used for this
purpose. In MCCV, the samples (cell lines) are randomly
partitioned into training sets and test sets. The marker
genes found to be significant in the training set are then
evaluated for their predictive accuracy in the test set. This
random partitioning process is iterated multiple times.
The 13 genes were consistently found to be significant
across the iterations. More details are described in [23]
(also, Das et al, in preparation). The final model was
determined via leave-one-out cross-validation. Ingenuity
Pathway Analysis (IPA 5.0; Ingenuity Software, Inc, CA,
USA) knowledgebase molecular interactome was applied
to the 250 predictor genes to identify the networks of
genes, generated algorithmically based on their connectiv-
ity. Network genes were further analysed for significant
pathways associations.
Results
Effect of polyamine analogue PG-11047 on breast cancer 
cell lines
Forty-two breast cancer cell lines representing luminal,
basal and claudin-low breast cancer subtypes and six non-
malignant breast cell lines were treated with PG-11047 in
doses ranging from 13 nM to 5 mM for 72 h. The GI50 dose
was calculated for each of the cell lines and ranged from
0.4 μM to 5 mM (Additional File 1) with a median GI50 at
31.5 μM. The distribution of GI50 values for the cell lines
arranged from most sensitive to most resistant is shown in
Figure 1 along with subtype classification. These data
show that the basal and claudin-low subtypes were inhib-
ited at the lowest levels of PG-11047 (P < 0.01; Mann-
Whitney test). The TGI (dose required to inhibit 100 per-
cent of the cell growth from T0) showed similar subtype
specificity (Additional File 1).
Predictive markers for PG-11047 response
We correlated the GI50 values for the cell lines in the panel
with their pretreatment genomic, transcriptional and pro-
teomic profiles in order to identify molecular factors asso-
ciated with cellular response to PG-11047. Additional
Files 2, 3 and 4 list mRNA, DNA and protein features that
were significantly associated with response. The molecu-
lar features associated with response or resistance when
present at elevated levels are listed as response predictors.
IPA of 250 mRNA transcripts significantly associated with
response showed several pathways as significantly associ-
ated with response (Table 1). The interferon signalling
pathway was most significantly involved in PG-11047
response, with four of the genes identified in the top 250
Growth inhibition (GI50) sensitivity profile of the breast cell lines to PG-11047 Figure 1
Growth inhibition (GI50) sensitivity profile of the breast cell lines to PG-11047. Cell lines are arranged from sensitive 
(left) to resistant (right) based on median centred GI50 value. Solid bar, basal; gray bar, claudin low; striped bar, luminal subtype; 
white bar, non-malignant breast cells.BMC Medicine 2009, 7:77 http://www.biomedcentral.com/1741-7015/7/77
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genes out of a total of 29 genes identified in the pathway.
Network connectivity analysis suggested interactions
among the 250 genes most significantly associated with
response. The most significant two networks are shown in
Figure 2. Network 1 involves basal cytokeratins, ubiqui-
tin/proteasome processes, RNA processing and histone
deacetylase. Network 2 involves interferon signalling.
Further analysis of the 250 mRNA transcript levels associ-
ated with response in the cell lines yielded a 13 gene sig-
nature as possible clinical predictor of response to PG-
11047 treatment (Table 2). Higher levels of expression of
WASL, CST3, DEAF1 and ACSL3 were associated with
resistance to PG-11047 while high expression levels of
GCLM, LAMA3, SSRP1, ACYP1, CYLD, PRPF18, AMFR,
PPP1R2 and LOH11CR2A were associated with increased
sensitivity. We evaluated the performance of the 13 gene
signature in predicting sensitivity of the cell-lines to PG-
11047. The average correlation between predicted and
measured sensitivities was 0.93. Here, multiple random
samplings of training and test sets were performed. The
average reflects the performance of the predictive model
across these iterations in the test sets. The genes in this sig-
nature are involved in cell motility, response to stress and
cellular metabolic processes, based on the known func-
tions of the genes.
Correlative analysis of GI50 sensitivity of the cell line panel
with genomic copy number aberration (array comparative
genomic hybridization data) and protein level (Western
data) identified additional markers significantly associ-
ated with response. These are listed in Additional Files 3
and 4. Several of the 13 gene signature transcriptional
markers were found in regions of genomic abnormality
associated with response. Examples include: genomic
copy gains of the chromosomal regions near AMFR
(16q21), SSRP1 (11q12) and LOH11CR2A (11q23) and
copy number loss of CST3 (20p11.2) that predict sensitiv-
Table 1: Significant pathways from top 250 predictor genes associated with response to PG-11047 treatment using Ingenuity Pathway 
analysis.
Pathway Name P-Value Ratio Component genes in the pathway
Interferon Signaling 0.001 [4/29] IRF1, IRF9, TAP1, IFNGR1
Ephrin Receptor Signaling 0.011 [8/
193]
CXCR4, ABI1, RAP1A, MAPK1, WASL,
MAP4K4, GNAI3, PAK1
Role of BRCA1 in DNA Damage
Response
0.013 [4/52] RPA1, RFC3, MSH2, E2F3
Nicotinate and Nicotinamide
Metabolism
0.019 [5/
129]
NNMT, ENPP2, MAPK1, ENPP1, PAK1
Fcy Receptor -mediatedPhagocytosis in Macrophages 
andMonocytes
0.028 [5/
104]
RPS6KB1, LYN, MAPK1, VAMP3, PAK1
Riboflavin Metabolism 0.032 [2/49] ENPP2, ENPP1
Endoplasmic Reticulum Stress
Pathway
0.041 [2/18] XBP1, TAOK3
Pantothenateand CoA Biosynthesis 0.046 [2/63] ENPP2, ENPP1
CXCR4 Signaling 0.052 [6/
164]
CXCR4, RHOB, LYN, MAPK1, GNAI3, PAK1
PI3K/AKT Signaling 0.055 [5/
135]
RPS6KB1, SFN, MAPK1, YWHAH, PPP2R5A
Integrin Signaling 0.056 [7/
198]
RHOB, RAP1A, MAPK1, TSPAN6, WASL, ARF4, PAK1
Ratio indicates the number of genes in the top 250 predictors that belong to the pathway indicated over the number of genes known of the 
pathway. Genes in bold were associated with resistance when transcribed at high levels. Genes in normal fonts were associated with sensitivity 
when transcribed at high levels.BMC Medicine 2009, 7:77 http://www.biomedcentral.com/1741-7015/7/77
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ity to PG-11047 treatment (Additional File 3). These
observations are consistent with the predictors developed
with the mRNA expression data and suggest that genomic
aberrations may drive the changes in gene expression that
determine response to PG-11047. Interestingly, the status
of AKT was among the protein levels significantly associ-
ated with response (Additional file 4), with high phos-
pho-AKT associated with sensitivity and high AKT
associated with resistance. Not surprisingly, high level
expression of the basal subtype cytokeratins, CK5 and
CK6, were associated with sensitivity while high level
expression of the luminal cytokeratin, CK18 was associ-
ated with resistance.
PG-11047 mediated cell cycle changes
We examined the effect of PG-11047 on cell cycle distri-
bution and apoptosis in order to understand the mecha-
nism by which PG-11047-induced growth inhibition
occurred. Six sensitive and three resistant cell lines were
plated and treated as stated previously. These were
labelled with BrdUrd at 48 and 72 h after PG-11047 treat-
ment. The sensitive cell lines showed a greater reduction
in fraction of cells incorporating BrdUrd than did the
resistant cells. The cell cycle distributions of these cell
lines treated with 0.3, 10 and 300 μM of PG-11047 for 72
h are shown in Figure 3A. There was a significant decrease
in the fraction of cells in S-phase with increasing doses of
PG-11047 in the cell lines that showed highest sensitivity;
this effect was clearer at 72 h than at 48 h of exposure
(data not shown). The three resistant cell lines,
MDAMB436, MDAMB361 and SKBR3, showed only mod-
est changes in the fractions of cells in S-phase. Apoptosis,
measured with the Promega Caspase-Glo 3/7 assay, gener-
ally was induced at higher concentrations of PG-11047
than required to inhibit cell cycle traverse (Figure 3B) in
sensitive cell lines. These data suggest that the growth
inhibition induced by PG-11047 in these cell lines occurs
more through cell cycle inhibition than by induction of
apoptosis.
Discussion
Polyamines are required for cellular viability and elevated
levels are found in many tumour types, including breast
cancer [2], making polyamine synthesis an attractive tar-
get for chemotherapy. PG-11047 is a second generation
polyamine analogue specifically designed as a therapeutic
agent [7]. While it is reported to effectively inhibit cell
growth in lung, breast and colon cancer cell lines
Network analysis of the top 250 predictor genes Figure 2
Network analysis of the top 250 predictor genes. Ingenuity Pathway Analysis was applied to the top 250 predictor genes 
to identify gene networks based on connectivity (red: predictor of sensitivity, green: predictor of resistance). The top two net-
works are shown here. The network scores for networks 1 and 2 are 54 and 49, respectively. Nodes are displayed using 
shapes that represent the functional class of the gene product. Edges are displayed with labels that describe the nature of the 
relationship between the nodes. All edges are supported by at least 1 reference from the literature, or from canonical informa-
tion stored in the Ingenuity Pathways Knowledge Base.BMC Medicine 2009, 7:77 http://www.biomedcentral.com/1741-7015/7/77
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Table 2: Gene list predicting sensitivity (S) or resistance (R) to PG-11047 treatment.
Gene symbol P-value Predict Chromosome 
location
Gene name Function References
WASL 2.5E-05 R chr7q31.3 Wiskott-Aldrich syndrome-like Key regulator of cell migration and 
actin polymerization by interaction 
with Ap2/3 complex
[32,47]
GCLM 4.7E-05 S chr1p22.1 Glutamate-cysteine ligase, 
modifier subunit
Regulatory subunit of glutamate-
cystein ligase, a rate-limiting enzyme 
catalyzing the first step of GSK 
biosynthesis from cysteine
[39]
CST3 6.3E-05 R chr20p11.21 Cystatin C (amyloid angiopathy 
and cerebral haemorrhage)
Potent inhibitor of lysosomal 
proteinases. TGFβ receptor 
antagonist, inhibit epithelial-
mesenchymal transition and 
morphological transformation
[30]
LAMA3 6.7E-05 S chr18q11.2 Laminin, alpha 3 Component of laminin 5, the major 
extracellular metrix protein produced 
in the basement membrane of the 
mammary epithelial cells. Induces 
motility, invasion and epithelial-
mesenchymal transition
[35,48]
SSRP1 1.2E-04 S chr11q12 Structure specific recognition 
protein 1
Histone chaperone. Forms a 
heterodimer with Spt16 and is a 
component of the chromatin 
transcript regulation factor, FACT
[40,42]
ACYP1 1.2E-04 S chr14q24.3 Acylphosphatase 1, erythrocyte 
(common) type
Catalyze the hydroolysis of 
acylphosphates
[49]
CYLD 2.9E-04 S chr16q12.1 Cylindromatosis 
(turban tumour syndrome)
A deubiquinating enzyme that 
negatively regulate the activity of 
NFkB and JNK. Regulate mitotic entry
[43,45]
PRPF18 3.0E-04 S chr10p13 PRP18 pre-mRNA processing 
factor 18 homolog 
(Saccharomyces cerevisiae)
Participate in pre-mRNA splicing, 
prepare mRNA for translation
[41]
AMFR 3.1E-04 S chr16q21 Autocrine motility factor 
receptor
Receptor for AMF, a tumour motility-
stimulating protein secreted by 
tumour cells. Stimulation of AMFR by 
AMF alters cellular adhesion, 
proliferation, motility and apoptosis
[33,36]
DEAF1 7.9E-04 R chr11p15.5 Deformed epidermal 
autoregulatory factor 1 
(Drosophila)
A sequence-specific DNA-binding 
protein required for development. 
May be a general regulator of gene 
transcription/expression. DEAF1 (also 
called 'suppressin') appear to be 
mutated in tumours and cell lines
[50,51]
PPP1R2 1.5E-03 S chr3q29 Protein phosphatase 1, 
regulatory (inhibitor) subunit 2
Inhibitor of protein phosphatase 1. 
Phosphorylation of PPP1R2 by 
glycogen synthase kinase-3 (GSK3) 
activates the enzyme. PPP1R2 (INH2) 
regulates PP1 complexed with NEK2 
to induce centrosome separation
[44]BMC Medicine 2009, 7:77 http://www.biomedcentral.com/1741-7015/7/77
Page 8 of 11
(page number not for citation purposes)
[7,12,24], only a limited number of cell lines had previ-
ously been studied. Since breast cancer is now known to
be comprised of multiple genomic and transcriptional
subsets [10,14] that progress and respond to therapy dif-
ferently, we analysed quantitative responses to PG-11047
in a collection of 42 breast cancer and six non-malignant
breast cell lines in order to identify biological and molec-
ular features associated with response. Figure 1 shows that
the basal subtype is most strongly inhibited by treatment
with PG-11047, based on GI50 response profiles. Basal
subtype breast cell lines mirror many molecular features
of basal-like primary breast tumours [15,16] including
low expression of oestrogen receptor and ERBB2 and high
expression of keratin 5/6/14 and EGFR (Spellman et al.,
personal communication). This suggests that, PG-11047
may be preferentially effective against this more aggressive
breast cancer subtype. This is consistent with observations
made in a study of the polyamine analogue, N1,  N11-
diethylnorspermine (DENSPM) [25]. An analysis of
BrdUrd incorporation and apoptosis induction in sensi-
tive and resistant cell lines suggests that responses to
micromolar concentrations of PG-11047 mainly involve
reduced cell cycle traverse rather than induction of apop-
tosis. Holst et al. [13] also reported inhibition of growth
in the breast cancer cell lines with PG-11047, although
they observed a stronger apoptotic response. This discrep-
ancy might be explained by differences in assay condi-
tions, since they assessed apoptosis as an increase in the
LOH11CR2A 1.7E-03 S chr11q23 Loss of heterozygosity, 11, 
chromosomal region 2, gene A
Frequent loss of heterozygosity at 
11q23 region found in many tumour 
types
[46]
ACSL3 1.8E-03 R chr2q34-q35 Acyl-CoA synthetase long-chain 
family member 3
Essential for fatty acid metabolism, 
providing activated intermediates for 
complex lipid synthesis, protein 
modification, and beta oxidation
[52]
Table 2: Gene list predicting sensitivity (S) or resistance (R) to PG-11047 treatment. (Continued)
Cell cycle distribution and apoptotic fraction of PG-11047 treated breast cancer cell lines Figure 3
Cell cycle distribution and apoptotic fraction of PG-11047 treated breast cancer cell lines. Six sensitive (top two 
rows) and three resistant (bottom row) cell lines were tested with PG-11047 for 72 h. (A) Fractions of cells estimated to be in 
the G1 (gray bar), S (black bar) and G2/M (white bar) phases of the cell cycle. (B) Corresponding relative apoptotic activity 
normalized to untreated control relative cell number.BMC Medicine 2009, 7:77 http://www.biomedcentral.com/1741-7015/7/77
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fraction of cells showing sub-G1 DNA content, while our
study was based on analysis of apoptosis related caspases
The concentration of drug needed to inhibit growth meas-
ured as GI50 or TGI ranged over four orders of magnitude
which meant that molecular features associated with
response could be identified with confidence. The correla-
tion of transcription profiles of the cell lines with their
GI50 sensitivity identified 250 genes whose expression lev-
els were associated with response to PG-11047. Network
and pathway analyses of these genes are summarized in
Figure 2 and Table 1. Increased interferon signaling was
implicated with increased sensitivity to PG-11047 by both
pathway and network analyses (Network 2). This is con-
sistent with the observation that interferon inhibits the
activity of ornithine decarboxylase (ODC) [26]. We spec-
ulate that cells with high interferon activity are preferen-
tially sensitive to PG-11047 because interferon-induced
down regulation of ODC reduces the endogenous pool of
the polyamines with which PG-11047 must compete to
affect its inhibitory functions. Other signalling pathways
and networks implicated in Table 1 and Figure 2 have
been reported to be differentially active in basal and lumi-
nal tumours and cell lines. For example, pathway activi-
ties associated with basal subtype tumours involve Ephrin
receptor [14,27], BRCA1 [28] and integrins [29]. The
strong basal subtype specificity of PG-11047 probably
explains the associations with these pathway activities.
Differential sensitivity of basal and luminal cells to PG-
11047 also probably explains the structure of Network 1
in Figure 2, since this network included several genes with
strong subtype specific expression [14].
A further analysis of the 250 genes associated with
response to PG-11047 identified 13 genes whose levels
were strongly and independently associated with response
(Table 2). We propose that a clinical response predictor
could be generated by assaying the levels of expression of
these genes. To this end, we evaluated the applicability of
the 13 gene set in stratifying breast tumour transcription
datasets. We used the model to predict the sensitivities of
the tumour samples in the Chin et al. [11] tumour panel
(total = 118 samples). We found that there is a tendency
toward separation between the predicted sensitivities of
basal versus non-basal tumours (P = 0.08). The stratifica-
tion improved if we restricted the analysis to high confi-
dence predictions of the model (89/118 samples): P =
0.01. This analysis supports the utility of PG-11047 in the
treatment of basal-subtype tumours.
Assessments of the contributions of these 13 response-
associated-genes to breast cancer pathophysiology may
provide insights into breast cancer responses to PG-11047
that were not directly tested in this study. Table 2 shows
that increased sensitivity to PG-11047 is associated with
lower expression of WASL, CST3, DEAF1 and ACSL3 and
higher expression of GCLM, LAMA3, SSRP1, ACYP1,
CYLD, PRPF18, AMFR, PPP1R2 and LOH11CR2A.
Several of these associations suggest that PG-11047 may
act to inhibit aspects of migration/metastasis. For exam-
ple, the protein encoded by CST3 is an antagonist of TGF-
β signaling and has been shown to be significantly down
regulated in many breast cancers [30]. Thus, PG-11047
may be preferentially effective in cells with active TGF-β
signaling, a phenotype that has been associated with
aggressive cancer behavior including increased migration/
metastasis [31] Reduced expression of WASL and
increased expression of AMFR also have been reported in
breast cancer tissue [32,33] and associated with cellular
migration [33-35]. Increased AMFR expression also is
associated with increased phospho-AKT levels in primary
human breast cancers [36]. Consistent with this, we
observed that a higher protein level of phospho-AKT is a
significant predictor for PG-11047 sensitive cells (Addi-
tional File 4). The implication of PG-11047 as an inhibi-
tor of motility/metastasis is further supported by the fact
that aspects of motility are known to be regulated by
polyamines [37]. The associations of gains of the chromo-
somal regions near AMFR (16q21) and loss near CST3
(20p11.2) suggests that the associations of gene expres-
sion changes with motility/metastasis and that response
to PG-11047 may be driven by genomic abnormalities.
Gene function assessments also suggest that PG-11047
may moderate aspects of epithelial to mesenchymal tran-
sition that are associated with aggressive clinical behav-
iour. For example, Carpenter et al. [38] have recently
shown that laminin 5 may contribute to increased tumour
aggressiveness resulting from epithelial to mesenchymal
transition (EMT) in breast tumours. Increased expression
of LAMA3, a subunit of laminin 5, is associated with
response to PG-11047 suggesting the possibility that
tumours responding to the drug also may experience
reduced EMT. Among the other genes associated with
response, GCLM and SSRP1 have been implicated in stress
response [39,40], PRPF18 and SSRP1 are involved with
transcription/translation [41,42], CYLD and PPP1R2 are
involved with cell cycle regulation [43,44] and CYLD and
LOH11CR2A have been reported as anti-oncogene/
tumour suppressor genes [45,46].
Conclusions
We assessed the quantitative responses of 48 breast cell
lines to PG-11047 and demonstrated that there is a wide
range of response to treatment. Our studies suggest that
basal-subtype breast cancers are preferentially sensitive to
the drug and that response at lower treatment concentra-
tions is cytostatic rather than apoptotic. Analysis of
molecular features associated with response suggests that
PG-11047 may also reduce metastasis-related motility
and suppress the EMT phenotype. We have generated a 13BMC Medicine 2009, 7:77 http://www.biomedcentral.com/1741-7015/7/77
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gene set response signature to identify tumours expected
to respond best to PG-11047 that may be useful in the
selection of patients for further evaluation of PG-11047.
Abbreviations
BESpm: bisethylspermine; BrdUrd: bromodeoxyuridine;
CTG: CellTiter-Glo; GI: growth inhibition; EMT: epithelial
to mesenchymal transition; IPA: Ingenuity Pathway Anal-
ysis; GI50: 50% GI; TGI: total growth inhibition; MCCV:
Monte Carlo cross validation; ODC: ornithine decarboxy-
lase; PBS: phosphate-buffered saline.
Competing interests
LJM is an employee of Progen Pharmaceuticals. This work
was supported in part by grant from Progen Pharmaceuti-
cals.
Authors' contributions
WK, RMN, JWG, LJM, ZH, NJW and HSF made substantial
contributions to the conception and design of the study.
WK, SZ and NB carried out the experiments and helped
with the data acquisition. WK, SZ, DD, SB, PTS, WJB,
LMH, AS and GVF helped with analysis and interpretation
of the data. WK, DD, SZ, AJW, PTS, LJM and JWG were
involved in drafting or critically revising the manuscript
for important intellectual content. All authors gave their
final approval of the version to be published.
Additional material
Acknowledgements
This work was supported by the Director, Office of Science, Office of Bio-
logical & Environmental Research, of the US Department of Energy under 
contract No. DE-AC02-05CH11231, by the National Institutes of Health, 
National Cancer Institute grants U54 112970, P50 CA 58207 and by a Pro-
gen Corporation grant to JWG.
References
1. Cohen SS: A Guide to the Polyamines.  New York: Oxford Uni-
versity Press; 1998. 
2. Casero RA Jr, Marton LJ: Targeting polyamine metabolism and
function in cancer and other hyperproliferative diseases.  Nat
Rev Drug Discov 2007, 6(5):373-390.
3. Saunders LR, Verdin E: Ornithine decarboxylase activity in
tumour cell lines correlates with sensitivity to cell death
induced by histone deacetylase inhibitors.  Mol Cancer Ther
2006, 5(11):2777-2785.
4. Levin VA, Hess KR, Choucair A, Flynn PJ, Jaeckle KA, Kyritsis AP,
Yung WK, Prados MD, Bruner JM, Ictech S, et al.: Phase III rand-
omized study of postradiotherapy chemotherapy with com-
bination alpha-difluoromethylornithine-PCV versus PCV for
anaplastic gliomas.  Clin Cancer Res 2003, 9(3):981-990.
5. Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter
PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, et al.: Dif-
luoromethylornithine plus sulindac for the prevention of
sporadic colorectal adenomas: a randomized placebo-con-
trolled, double-blind trial.  Cancer Prev Res Phila Pa 2008,
1(1):32-38.
6. Casero RA Jr, Woster PM: Recent advances in the development
of polyamine analogues as antitumour agents.  J Med Chem
2009, 52(15):4551-4573.
7. Reddy VK, Valasinas A, Sarkar A, Basu HS, Marton LJ, Frydman B:
Conformationally restricted analogues of 1N,12N-bisethyl-
spermine: synthesis and growth inhibitory effects on human
tumor cell lines.  J Med Chem 1998, 41(24):4723-4732.
8. Hacker A, Marton LJ, Sobolewski M, Casero RA Jr: In vitro and in
vivo effects of the conformationally restricted polyamine
analogue CGC-11047 on small cell and non-small cell lung
cancer cells.  Cancer Chemother Pharmacol 2008, 63(1):45-53.
9. Perou CM, Sørlie T, Eisen MB, Rijn M van de, Jeffrey SS, Rees CA, Pol-
lack JR, Ross DT, Johnsen H, Akslen LA, et al.: Molecular portraits
of human breast tumors.  Nature 2000, 406(6797):747-752.
10. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S,
Johnsen H, Pesich R, Geisler S, et al.: Repeated observation of
breast tumor subtypes in independent gene expression data
sets.  Proc Natl Acad Sci USA 2003, 100(14):8418-8423.
11. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL,
Lapuk A, Neve RM, Qian Z, Ryder T, et al.: Genomic and tran-
scriptional aberrations linked to breast cancer pathophysiol-
ogies.  Cancer Cell 2006, 10(6):529-541.
12. Davidson NE, Hahm HA, McCloskey DE, Woster PM, Casero RA Jr:
Clinical aspects of cell death in breast cancer: the polyamine
pathway as a new target for treatment.  Endocr Relat Cancer
1999, 6(1):69-73.
13. Holst CM, Frydman B, Marton LJ, Oredsson SM: Differential
polyamine analogue effects in four human breast cancer cell
lines.  Toxicology 2006, 223(1-2):71-81.
14. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bay-
ani N, Coppe JP, Tong F, et al.: A collection of breast cancer cell
lines for the study of functionally distinct cancer subtypes.
Cancer Cell 2006, 10(6):515-527.
Additional file 1
Growth inhibition response (GI50, TGI) to PG-11047 and molecular fea-
tures of breast cell lines. GI50 and TGI for members of the breast cell lines 
calculated as describe in Methods are listed in decreasing GI50 sensitivity 
with subtype classification and ER/PR/HER2 status reported by Neve et 
al. [14] and Spellman et al. (personal communication).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1741-
7015-7-77-S1.PDF]
Additional file 2
Statistically significant mRNA markers of response to PG-11047 (top 250 
genes). Markers generated by correlation of growth inhibition (GI50) sen-
sitivity with expression data of the cell lines reported by Neve et al[14].
Click here for file
[http://www.biomedcentral.com/content/supplementary/1741-
7015-7-77-S2.PDF]
Additional file 3
Statistically significant genomic markers (BAC clones) of response to PG-
11047. Markers generated by correlation of growth inhibition (GI50) sen-
sitivity with array CGH data of the cell lines reported by Neve et al. [14]. 
Bold text indicates clones located at or near four of the predictive markers. 
The chromosomal locations of these four predictive markers are also listed.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1741-
7015-7-77-S3.PDF]
Additional file 4
Statistically significant protein markers of response to PG-11047. Mark-
ers generated by correlation of growth inhibition (GI50) sensitivity with 
Western profile data of the cell lines reported by Neve et al. [14].
Click here for file
[http://www.biomedcentral.com/content/supplementary/1741-
7015-7-77-S4.PDF]BMC Medicine 2009, 7:77 http://www.biomedcentral.com/1741-7015/7/77
Page 11 of 11
(page number not for citation purposes)
15. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernan-
dez-Boussard T, Livasy C, Cowan D, Dressler L, et al.: Immunohis-
tochemical and clinical characterization of the basal-like
subtype of invasive breast carcinoma.  Clin Cancer Res 2004,
10(16):5367-5374.
16. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou
CM, Nielsen TO: Basal-like breast cancer defined by five
biomarkers has superior prognostic value than triple-nega-
tive phenotype.  Clin Cancer Res 2008, 14(5):1368-1376.
17. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ,
Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, et al.:
Characterization of a naturally occurring breast cancer sub-
set enriched in epithelial-to-mesenchymal transition and
stem cell characteristics.  Cancer Res 2009, 69(10):4116-4124.
18. NCI/NIH Developmental Therapeutic Program, Human Tumour Cell
Line Screen:  [http://dtp.nci.nih.gov/branches/btb/ivclsp.html].
19. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D,
Hose C, Langley J, Cronise P, Vaigro-Wolff A, et al.: Feasibility of a
high-flux anticancer drug screen using a diverse panel of cul-
tured human tumor cell lines.  J Natl Cancer Inst 1991,
83(11):757-766.
20. Dolbeare F, Gratzner H, Pallavicini MG, Gray JW: Flow cytometric
measurement of total DNA content and incorporated bro-
modeoxyuridine.  Proc Natl Acad Sci USA 1983, 80(18):5573-5577.
21. Das D, Nahle Z, Zhang MQ: Adaptively inferring human tran-
scriptional subnetworks.  Molecular systems biology 2006,
2:2006-0029.
22. Storey JD, Tibshirani R: Statistical significance for genomewide
studies.  Proceedings of the National Academy of Sciences of the United
States of America 2003, 100(16):9440-9445.
23. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA,
Booser D, Theriault RL, Buzdar AU, Dempsey PJ, et al.: Pharmacog-
enomic predictor of sensitivity to preoperative chemother-
apy with paclitaxel and fluorouracil, doxorubicin and
cyclophosphamide in breast cancer.  J Clin Oncol 2006,
24(26):4236-4244.
24. Ignatenko NA, Yerushalmi HF, Pandey R, Kachel KL, Stringer DE,
Marton LJ, Gerner EW: Gene expression analysis of HCT116
colon tumour-derived cells treated with the polyamine ana-
log PG-11047.  Cancer Genomics Proteomics 2009, 6(3):161-175.
25. Myhre L, Alm K, Hegardt C, Staaf J, Jönsson G, Larsson S, Oredsson
SM: Different cell cycle kinetic effects of N1, N11-diethylnor-
spermine-induced polyamine depletion in four human breast
cancer cell lines.  Anticancer Drugs 2008, 19(4):359-368.
26. Satriano J, Ishizuka S, Archer DC, Blantz RC, Kelly CJ: Regulation of
intracellular polyamine biosynthesis and transport by NO
and cytokines TNF-alpha and IFN-gamma.  Am J Physiol 1999,
276:C892-899.
27. Macrae M, Neve RM, Rodriguez-Viciana P, Haqq C, Yeh J, Chen C,
Gray JW, McCormick F: A conditional feedback loop regulates
Ras activity through EphA2.  Cancer Cell 2005, 8(2):111-118.
28. Palacios J, Robles-Frias MJ, Castilla MA, Lopez-Garcia MA, Benftez J:
The molecular pathology of herediatary breast cancer.  Patho-
biology 2008, 75(2):85-94.
29. Lu S, Simin K, Khan A, Mercurio AM: Analysis of integrin beta4
expression in human breast cancer: association with basal-
like tumors and prognostic soignificance.  Clin Cancer Res 2008,
14(4):1050-1058.
30. Yano M, Hirai K, Naito Z, Yokoyama M, Ishiwata T, Shiraki Y,
Inokuchi M, Asano G: Expression of cathepsin B and cystatin C
in human breast cancer.  Surg Today 2001, 31(5):385-389.
31. Padau D, Massague J: Roles of TGFbeta in metastasis.  Cell Res
2009, 19(1):89-102.
32. Martin TA, Pereira G, Watkins G, Mansel RE, Jiang WG: N-WASP
is a putative tumour suppressor in breast cancer cells, in vitro
and in vivo and is associated with clinical outcome in patients
with breast cancer.  Clin Exp Metastasis 2008, 25(2):97-108.
33. Jiang WG, Raz A, Douglas-Jones A, Mansel RE: Expression of auto-
crine motility factor (AMF) and its receptor, AMFR, in
human breast cancer.  J Histochem Cytochem 2006, 54(2):231-241.
34. Prehoda KE, Scott JA, Mullins RD, Lim WA: Integration of multi-
ple signals through cooperative regulation of the N-WASP-
Arp2/3 complex.  Science 2000, 290(5492):801-806.
35. Kariya Y, Miyazaki K: The basement membrane protein lam-
inin-5 acts as a soluble cell motility factor.  Exp Cell Res 2004,
297:508-520.
36. Kojic LD, Joshi B, Lajoie P, Le PU, Cox ME, Turbin DA, Wiseman SM,
Nabi IRWH, Raz A: Raft-dependent endocytosis of autocrine
motility factor is phosphatidylinositol 3-kinase-dependent in
breast carcinoma cells.  J Biol Chem 2007, 282(40):29305-29313.
37. McCormack SA, Johnson LR: Polyamines and cell migration.  J
Physiol Pharmacol 2001, 52(3):327-349.
38. Carpenter PM, Wang-Rodriguez J, Chan OT, Wilczynski SP: Laminin
5 expression in metaplastic breast carcinomas.  Am J Surg
Pathol 2008, 32(3):345-353.
39. Song IS, Tatebe S, Dai W, Kuo MT: Delayed mechanism for
induction of gamma-glutamylcysteine synthetase heavy sub-
unit mRNA stability by oxidative stress involving p38
mitogen-activated protein kinase signaling.  J Biol Chem 2005,
280(31):28230-28240.
40. Li Y, Keller DM, Scott JD, Lu H: CK2 phosphorylates SSRP1 and
inhibits its DNA-binding activity.  J Biol Chem 2005,
280(12):11869-11875.
41. Horowitz DS, Lee EJ, Mabon SA, Misteli T: A cyclophilin functions
in pre-mRNA splicing.  EMBO J 2002, 21(3):470-480.
42. Reinberg D, Sims RJ: de FACTo nucleosome dynamics.  J Biol
Chem 2006, 281(33):23297-23301.
43. Stegmeier F, Sowa ME, Nalepa G, Gygi SP, Harper JW, Elledge SJ: The
tumour suppressor CYLD regulates entry into mitosis.  Proc
Natl Acad Sci USA 2007, 104(21):8869-8874.
44. Eto M, Elliott E, Prickett TD, Brautigan DL: Inhibitor-2 regulates
protein phosphatase-1 complexed with NimA-related kinase
to induce centrosome separation.  J Biol Chem 2002,
277(46):44013-44020.
45. Kovalenko A, Chable-Bessia C, Cantarella G, Israël A, Wallach D,
Courtois G: The tumour suppressor CYLD negatively regu-
lates NF-kappaB signalling by deubiquitination.  Nature 2003,
424(6950):801-805.
46. Monaco C, Negrini M, Sozzi G, Veronese ML, Vorechovsky I, Godwin
AK, Croce CM: Molecular cloning and characterization of
LOH11CR2A, a new gene within a refined minimal region of
LOH at 11q23.  Genomics 1997, 46(2):217-222.
47. Antón IM, Jones GE, Wandosell F, Geha R, Ramesh N: WASP-inter-
acting protein (WIP): working in polymerisation and much
more.  Trends Cell Biol 2007, 17(11):555-562.
48. Sathyanarayana UG, Padar A, Huang CX, Suzuki M, Shigematsu H,
Bekele BN, Gazdar AF: Aberrant promoter methylation and
silencing of laminin-5-encoding genes in breast carcinoma.
Clin Cancer Res 2003, 9(17):6389-6394.
49. Fiaschi T, Marzella R, Veggi D, Marzocchini R, Raugei G, Rocchi M,
Ramponi G: Assignment of the human erythrocyte acylphos-
phatase gene (ACYP1) to chromosome band 14q24.3.
Cytogenet Cell Genet 1998, 81:235-236.
50. Barker HE, Smyth GK, Wettenhall J, Ward TA, Bath ML, Lindeman GJ,
Visvader JE: Deaf-1 regulates epithelial cell proliferation and
side-branching in the mammary gland.  BMC Dev Biol 2008,
8:94-107.
51. Manne U, Gary BD, Oelschlager DK, Weiss HL, Frost AR, Grizzle
WE: Altered subcellular localization of suppressin, a novel
inhibitor of cell-cycle entry, is an independent prognostic fac-
tor in colorectal adenocarcinomas.  Clin Cancer Res 2001,
7(11):3495-3503.
52. Yao H, Ye J: Long chain acyl-CoA synthetase 3-mediated phos-
phatidylcholine synthesis is required for assembly of very low
density lipoproteins in human hepatoma Huh7 cells.  J Biol
Chem 2008, 283(2):849-854.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1741-7015/7/77/prepub